News for Eisai Co., Ltd. (ESALF)

**media[559052]**

Boston (March 3, 2025)””Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated

Biogen Inc (BIIB) and Eisai Co., Ltd. announced on February 28, 2025, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines A

PR NewswireTOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: H

Boston (February 26, 2025)””Allarity Therapeutics, Inc. (”œAllarity” or the ”œCompany”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicate

Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP C

**media[540845]**

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O N4523.T - Eisai Co LtdQ3 2025 Eisai Co Ltd Earnings PresentationFeb 07, 2025 / 06:00AM GMT ====

Eisai Co., Ltd. (OTCPK:ESALF) Q3 2024 Earnings Call Transcript February 7, 2025 1:00 AM ETCompany ParticipantsHaruo Naito - Representative Corporate Officer...

**media[534054]**

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Biogen Inc.

**media[528937,528938]**

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corpo…

TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2

Biogen Inc (BIIB) and Eisai Co., Ltd. have announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologics License Application

Biogen Inc (BIIB) and Eisai Co., Ltd. have announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologics License Application

**media[524630,524631]**

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

Merck and Eisai report mixed results in Phase 3 cancer trial